Skip to main content

Quince Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

QNCX$31.73+8.1%Stored close · as of Oct 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Page
PART I. · FINANCIAL INFORMATION
Item 1.Financial Statements (Unaudited)1
Condensed Consolidated Balance Sheets (Unaudited)1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)2
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited)3
Condensed Consolidated Statements of Cash Flows (Unaudited)4
Notes to Unaudited Condensed Consolidated Financial Statements5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27
Item 3.Quantitative and Qualitative Disclosures About Market Risk35
Item 4.Controls and Procedures35
PART II.OTHER INFORMATION
Item 1.Legal Proceedings36
Item 1A.Risk Factors36
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds37
Item 3.Defaults Upon Senior Securities37
Item 4.Mine Safety Disclosures37
Item 5.Other Information37
Item 6.Exhibits38
Signatures40

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "expect," "objective," "plan," "potential," "seek," "grow," "target," "if," and similar expressions intended to identify forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (the "SEC"). It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

our ability to successfully execute on our current strategic direction, including our ability to pursue strategic alternatives, such as completing a reverse merger or selling assets;

our financial performance;

our ability to continue as a going concern, the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and debt service requirements;

the accuracy of our estimates regarding expenses, liquidity requirements, and needs for additional financing;

our expectations related to the use of our available cash;

our ability to obtain funding for our operations;

our ability to attract and retain key personnel;

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;

potential claims relating to our intellectual property; and

our ability to maintain compliance with Nasdaq listing requirement.

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.

You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or revised expectations.

You should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

This Quarterly Report on Form 10-Q contains estimates, projections and other information concerning our industry, our business and the markets for our drug candidates. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.

DEFINED TERMS

Unless the context requires otherwise, references to “Quince,” “the Company,” “we,” “us,” or “our” in this Quarterly Report on Form 10-Q refer to Quince Therapeutics, Inc. and its consolidated subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below.

Abbreviated TermDefined Term
AIDEAutologous Intracellular Drug Encapsulation
ASCAccounting Standards Codification
ASUAccounting Standards Update
A-TAtaxia-Telangiectasia
the CodeInternal Revenue Code of 1986, as amended
CODMChief Operating Decision Maker
Debt AgreementUnsecured line of credit agreement between EryDel and the European Investment Bank, which the Company guaranteed on October 20, 2023 in connection with the EryDel Acquisition
DSPDexamethasone Sodium Phosphate
ECEuropean Commission
EryDelQuince Therapeutics, S.p.A (previously named EryDel S.p.A.)
eDSPEncapsulated dexamethasone sodium phosphate encapsulated in patient's own red blood cells (previously referred to as EryDex)
eDSP SystemAutomated combination product to encapsulate dexamethasone sodium phosphate in red blood cells
EIBEuropean Investment Bank
EUEuropean Union
EIB LoanUnsecured line of credit between EryDel and the European Investment Bank
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAUnited States Food and Drug Administration
GAAPgenerally accepted accounting principles in the United States
ICARSInternational Cooperative Ataxia Rating Scale
IPR&DIn-process Research and Development
LighthouseLighthouse Pharmaceuticals, Inc.
NasdaqThe Nasdaq Stock Market LLC
NDANew Drug Application
NEATeDSP Phase 3 Clinical Trial (Neurological Effects of eDSP on Subjects with A-T)
NovosteoNovosteo, Inc.
OLEOpen-Label Extension Clinical Trial
R&DResearch and Development
RSURestricted Stock Units
Sarbanes-Oxley ActThe Sarbanes-Oxley Act of 2002
SECUnited States Securities and Exchange Commission
Securities ActSecurities Act of 1933
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.